SCHEMBL2194676

SCHEMBL2194676

Cc1cccc(Nc2nc(O)ccc2N)c1Br

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NUDT1 P36639 1/20 0.33
RET P07949 1/20 0.33
KIF5B P33176 1/20 0.33
KDR P35968 1/20 0.33
MAPT P10636 4/20 0.33
ALDH1A1 P00352 3/20 0.33
GAA P10253 3/20 0.33
ALOX15 P16050 2/20 0.33
LMNA P02545 2/20 0.33
HTT P42858 2/20 0.33
PABPC1 P11940 1/20 0.33
KDM4E B2RXH2 1/20 0.33
CASP1 P29466 1/20 0.33
CASP7 P55210 1/20 0.33
RUNX1 Q01196 1/20 0.33
CBFB Q13951 1/20 0.33
HSD17B10 Q99714 1/20 0.33
CYP3A4 P08684 1/20 0.33
THRB P10828 1/20 0.33
RECQL P46063 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2191767 0.85 NUDT1 (0.47) NUDT1MAPTALDH1A1GAALMNA
SCHEMBL2195364 0.78 KMT2A (0.41) MAPTGAALMNAHTTHSD17B10
SCHEMBL2193522 0.77 PIK3CD (0.39) NUDT1MAPTALDH1A1GAAHTT
SCHEMBL2192571 0.77 MAPT (0.50) MAPTALDH1A1GAALMNACYP3A4
SCHEMBL2196525 0.75 EPHX2 (0.48) KDRMAPTALDH1A1GAAALOX15
SCHEMBL2192677 0.74 EGFR (0.38) RETKIF5BKDRMAPTGAA
SCHEMBL2193574 0.74 KHK (0.39) MAPTALDH1A1ALOX15HTTHSD17B10
SCHEMBL2192476 0.73 MAPT (0.44) MAPTALDH1A1LMNAHTTKDM4E
SCHEMBL2193744 0.73 PDE5A (0.46) MAPTALDH1A1KDM4EHSD17B10MEN1
SCHEMBL2191511 0.72 EGFR (0.46) ALDH1A1HTTKDM4ETDP1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8507473-B2 3H-imidazo[4,5-b]pyridin-5-ol derivatives useful in the treatment of GPR81 receptor disorders ARENA PHARMACEUTICALS, INC. (US) 2013-08-13 US disclosed
US-20110172209-A1 3H-IMIDAZO[4,5-B]PYRIDIN-5-OL DERIVATIVES USEFUL IN THE TREATMENT OF GPR81 RECEPTOR DISORDERS ARENA PHARMACEUTICALS, INC. (US) 2011-07-14 US disclosed
WO-2010030360-A1 3H-IMIDAZO[4,5-b]PYRIDIN-5-OL DERIVATIVES USEFUL IN THE TREATMENT OF GPR81 RECEPTOR DISORDERS ARENA PHARMACEUTICALS, INC. (US) 2010-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172209-A1 3H-IMIDAZO[4,5-B]PYRIDIN-5-OL DERIVATIVES USEFUL IN THE TREATMENT OF GPR81 RECEPTOR DISORDERS GPR84, GPR119, GPR65 NUDT1 3253/4885RET 1347/4885KIF5B 4052/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.